

What is claimed is:

1. A pharmaceutical composition comprising celecoxib; a first excipient which is a propylene glycol fatty acid monoester; a second excipient selected from the group consisting of a polyethylene glycol, a polyoxyl castor oil, and a polysorbate; and a third excipient selected from the group consisting of a propylene glycol fatty acid monoester, a polysorbate, a sorbitan fatty acid monoester, a poloxamer, a polyethylene glycol, a polyethylene glycol fatty acid monoester, and a polyoxyl castor oil.
2. The pharmaceutical composition of Claim 1, wherein second excipient is selected from the group consisting of polyethylene glycol 400, polyoxyl 35 castor oil and polysorbate 80.
3. The pharmaceutical composition of Claim 2, wherein the third excipient is selected from the group consisting of propylene glycol monolaurate, polysorbate 80, sorbitan monolaurate, poloxamer 331, polyethylene glycol 400 and polyethylene glycol 20 stearate.
4. The pharmaceutical composition of Claim 3, wherein the first excipient is propylene glycol monolaurate.
5. The pharmaceutical composition of Claim 4, wherein the first excipient comprises about 60% to about 70% by weight of the first, second and third excipients.
6. The pharmaceutical composition of Claim 5, wherein the second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.

7. A pharmaceutical composition comprising celecoxib; a first excipient which is a poloxamer; a second excipient selected from the group consisting of a propylene glycol fatty acid monoester, a polyoxamer, and a plant oil; and a third excipient selected from the group consisting of a propylene glycol fatty acid monoester, a poloxamer, a polysorbate and a sorbitan fatty acid monoester.
8. The pharmaceutical composition of Claim 7, wherein the second excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331 and sesame oil.
9. The pharmaceutical composition of Claim 8, wherein the third excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polysorbate 80, sesame oil and sorbital monolaurate.
10. The pharmaceutical composition of Claim 9, wherein the first excipient is poloxamer 331.
11. The pharmaceutical composition of Claim 10, wherein the first excipient comprises about 60% to about 70% by weight of the first, second and third excipients.
12. The pharmaceutical composition of Claim 11, wherein the second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.
13. A pharmaceutical composition comprising celecoxib; a first excipient which is a polyethylene glycol; a second excipient selected from the group consisting of a polyethylene glycol, a polyoxyl castor oil and a sorbitan fatty acid monoester; and a third excipient selected from the group consisting of a polyethylene glycol, a sorbitan fatty acid monoester and a propylene glycol fatty acid monoester.

14. The pharmaceutical composition of Claim 13, wherein the second excipient is selected from the group consisting of polyethylene glycol 400, polyoxyl 35 castor oil and sorbitan monolaurate.
15. The pharmaceutical composition of Claim 14, wherein the third excipient is selected from the group consisting of polyethylene glycol 400, sorbitan monolaurate and propylene glycol monolaurate.
16. The pharmaceutical composition of Claim 15, wherein the first excipient is polyethylene glycol 400.
17. The pharmaceutical composition of Claim 16, wherein the first excipient comprises about 60% to about 70% by weight of the first, second and third excipients.
18. The pharmaceutical composition of Claim 17, wherein the second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.
19. A pharmaceutical composition comprising celecoxib; a first excipient which is a sorbitan fatty acid monoester; a second excipient selected from the group consisting of a polyethylene glycol and a polysorbate; and a third excipient selected from the group consisting of a propylene glycol fatty acid monoester, a polyoxamer, a polyethylene glycol, a polyoxyl castor oil, a polysorbate, a plant oil or a sorbitan fatty acid monoester.
20. The pharmaceutical composition of Claim 19, wherein the second excipient is selected from the group consisting of polyethylene glycol 400 and polysorbate 80.
21. The pharmaceutical composition of Claim 20, wherein the third excipient is selected from the group of propylene glycol laurate, polyoxamer 331, polyethylene

- glycol 400, polyoxyl 35 castor oil, polysorbate 80, sesame oil and sorbitan monolaurate.
22. The pharmaceutical composition of Claim 21, wherein the first excipient is sorbitan monolaurate.
23. The pharmaceutical composition of Claim 22, wherein the first excipient comprises about 60% to about 70% by weight of the first, second and third excipients.
24. The pharmaceutical composition of Claim 23, wherein the second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.
25. A pharmaceutical composition comprising celecoxib; a first excipient which is a polyoxyl castor oil; a second excipient selected from the group consisting of a propylene glycol fatty acid monoester, a poloxamer, a polyethylene glycol, a polyoxyl castor oil, a polysorbate and a sorbitan fatty acid monoester; and a third excipient selected from the group consisting of a propylene glycol fatty acid monoester, a poloxamer, a polyethylene glycol, a polyoxyl castor oil, a polysorbate, a plant oil and a sorbitan fatty acid monoester.
26. The pharmaceutical composition of Claim 25, wherein the second excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80 and sorbitan monolaurate.
27. The pharmaceutical composition of Claim 26, wherein the third excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80, sorbitan monolaurate and sesame oil.

28. The pharmaceutical composition of Claim 27, wherein the first excipient is polyoxyl 35 castor oil.
29. The pharmaceutical composition of Claim 28, wherein the first excipient comprises about 60% to about 70% by weight of the first, second and third excipients.
30. The pharmaceutical composition of Claim 29, wherein the second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.
31. A pharmaceutical composition comprising celecoxib; a first excipient which is a polysorbate; a second excipient selected from the group consisting of a propylene glycol fatty acid monoester, a poloxamer, a polyethylene glycol, a polyoxyl castor oil, a polysorbate and a sorbitan fatty acid monoester; and a third excipient selected from the group consisting of a propylene glycol fatty acid monoester, a polyethylene glycol, a polyoxyl castor oil, a polysorbate a plant oil, a sorbitan fatty acid monoester and a poloxamer.
32. The pharmaceutical composition of Claim 31, wherein the second excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80 and sorbitan monolaurate.
33. The pharmaceutical composition of Claim 32, wherein the third excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80, sorbitan monolaurate and sesame oil.

34. The pharmaceutical composition of Claim 33, wherein the first excipient is polysorbate 80.
35. The pharmaceutical composition of Claim 34, wherein the first excipient comprises about 60% to about 70% by weight of the first, second and third excipients.
36. The pharmaceutical composition of Claim 35, wherein the second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.
37. A pharmaceutical composition comprising celecoxib; a first excipient which is polyoxyl 35 castor oil; and a second excipient which is selected from the group consisting of a propylene glycol fatty acid monoester, a polyethylene glycol, a polyoxyl castor oil, a polysorbate, a sorbitan fatty acid monoester, mono- and di-glycerides from plant oil, a monoglyceride of a hydroxylated fatty acid, tricarboxylic acids, tocopherol and a polyethylene glycol fatty acid ester.
38. The pharmaceutical composition of Claim 37, wherein the second excipient is selected from the group consisting of propylene glycol monolaurate, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80, sorbitan monolaurate, C<sub>8</sub> and C<sub>10</sub> mono- and di-glycerides from coconut oil, glyceryl ricinoleate, triacetin, tocopherol, polyethylene glycol 60 almond glycerides and polyethylene glycol 6 isostearate.
39. The pharmaceutical composition of Claim 38, wherein the first excipient comprises about 70% to about 80% by weight of the first and second excipients and the second excipient comprises about 20% to about 30% by weight of the first and second excipients.

40. A pharmaceutical composition comprising celecoxib; a first excipient which is polysorbate 80; and a second excipient selected from the group consisting of a propylene glycol monolaurate, a poloxamer, a polyethylene glycol, a polyoxyl castor oil, a sorbitan fatty acid monoester, mono- and di-glycerides from plant oil, a monoglyceride of a hydroxylated fatty acid, a tricarboxylic acid, tocopherol and a polyethylene glycol fatty acid ester.
41. The pharmaceutical composition of Claim 40, wherein the second excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polyethylene glycol 400, polyoxyl 35 castor oil, sorbitan monolaurate, C<sub>8</sub> and C<sub>10</sub> mono- and di-glycerides from coconut oil, glyceryl ricinoleate, triacetin, tocopherol and polyethylene glycol 60 almond glycerides.
42. The pharmaceutical composition of Claim 41, wherein the first excipient comprises about 70% to about 80% by weight of the first and second excipients and the second excipient comprises about 20% to about 30% by weight of the first and second excipients.
43. A pharmaceutical composition comprising celecoxib; a first excipient which is poloxamer 331; and a second excipient selected from the group consisting of a plant oil, mono- and di-glycerides from plant oil, a tricarboxylic acid and a polyethylene glycol fatty acid ester.
44. The pharmaceutical composition of Claim 43, wherein the second excipient is selected from the group consisting of sesame oil, C<sub>8</sub> and C<sub>10</sub> mono- and di-glycerides from coconut oil, triacetin and polyethylene glycol 6 isostearate.
45. The pharmaceutical composition of Claim 44, wherein the first excipient comprises about 70% to about 80% by weight of the first and second excipients and the second excipient comprises about 20% to about 30% by weight of the first and second excipients.

46. A pharmaceutical composition comprising celecoxib; a first excipient which is polyethylene glycol 400; and a second excipient selected from the group consisting of a polysorbate, a sorbitan fatty acid monoester, mono- and di-glycerides from plant oil, a monoglyceride of a hydroxylated fatty acid, a tricarboxylic acid, a trialkanolamine and a polyethylene glycol fatty acid ester.
47. The pharmaceutical composition of Claim 46, wherein the second excipient is selected from the group consisting of polysorbate 80, sorbitan monolaurate, C<sub>8</sub> and C<sub>10</sub> mono- and di-glycerides from coconut oil, glyceryl ricinoleate, triacetin, triethanolamine and polyethylene glycol 60 almond glycerides.
48. The pharmaceutical composition of Claim 47, wherein the first excipient comprises about 70% to about 80% by weight of the first and second excipients and the second excipient comprises about 20% to about 30% by weight of the first and second excipients.
49. A pharmaceutical composition comprising celecoxib; a first excipient which is polyethylene glycol 60 almond glycerides; and a second excipient selected from the group consisting of a propylene glycol fatty ester monoester, a polyethylene glycol, a polyoxyl castor oil, a polysorbate, a sorbitan fatty acid monoester, mono- and di-glycerides from plant oil, a monoglyceride of a hydroxylated fatty acid, a tricarboxylic acid, tocopherol and a polyethylene glycol fatty acid ester.
50. The pharmaceutical composition of Claim 49, wherein the second excipient is selected from the group consisting of propylene glycol monolaurate, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80, sorbitan monolaurate, C<sub>8</sub> and C<sub>10</sub> mono- and di-glycerides from coconut oil, glyceryl ricinoleate, triacetin, tocopherol and polyethylene glycol 6 isostearate.

51. The pharmaceutical composition of Claim 50, wherein the first excipient comprises about 70% to about 80% by weight of the first and second excipients and the second excipient comprises about 20% to about 30% by weight of the first and second excipients.
52. A pharmaceutical composition comprising celecoxib; a first excipient which is polyethylene glycol 6 isostearate; and a second excipient selected from the group consisting of a propylene glycol fatty acid monoester, a poloxamer, a polyoxyl castor oil, a polysorbate, a plant oil, mono- and di-glycerides from plant oil, a monoglyceride of a hydroxylated fatty acid, a tricarboxylic acid, tocopherol and a polyethylene glycol fatty acid ester.
53. The pharmaceutical composition of Claim 52, wherein the second excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80, sesame oil, C<sub>8</sub> and C<sub>10</sub> mono- and di-glycerides from coconut oil, coconut oil, glyceryl ricinoleate, triacetin, tocopherol and polyethylene glycol 60 almond glycerides.
54. The pharmaceutical composition of Claim 53, wherein the first excipient comprises about 70% to about 80% by weight of the first and second excipients and the second excipient comprises about 20% to about 30% by weight of the first and second excipients.
55. A pharmaceutical composition comprising celecoxib; a first excipient which is C<sub>8</sub> and C<sub>10</sub> mono- and di-glycerides from coconut oil; and a second excipient selected from the group consisting of a polyethylene glycol and a polyethylene glycol fatty acid ester.
56. The pharmaceutical composition of Claim 55, wherein the second excipient is selected from the group consisting of polyethylene glycol 400 and polyethylene glycol 20 stearate.

57. The pharmaceutical composition of Claim 56, wherein the first excipient comprises about 70% to about 80% by weight of the first and second excipients and the second excipient comprises about 20% to about 30% by weight of the first and second excipients.
58. A pharmaceutical composition comprising celecoxib; a first excipient which is triacetin; and a second excipient selected from the group consisting of a polyethylene glycol, a polyoxyl castor oil, and a polyethylene glycol fatty acid ester.
59. The pharmaceutical composition of Claim 58, wherein the second excipient is selected from the group consisting of polyethylene glycol 400, polyoxyl 35 castor oil, polyethylene glycol 60 almond glycerides and polyethylene glycol 6 isostearate.
60. The pharmaceutical composition of Claim 59, wherein the first excipient comprises about 70% to about 80% by weight of the first and second excipients and the second excipient comprises about 20% to about 30% by weight of the first and second excipients.
61. A pharmaceutical composition comprising celecoxib; a first excipient which is triethanolamine; and a second excipient selected from the group consisting of a polyethylene glycol and mono- and di-glycerides from plant oil.
62. The pharmaceutical composition of Claim 61, wherein the second excipient is selected from the group consisting of polyethylene glycol 400 and C<sub>8</sub> and C<sub>10</sub> mono- and di-glycerides from coconut oil.
63. The pharmaceutical composition of Claim 62, wherein the first excipient comprises about 70% to about 80% by weight of the first and second excipients and the

- second excipient comprises about 20% to about 30% by weight of the first and second excipients.
64. A pharmaceutical composition comprising celecoxib; tocopherol; and a polyethylene glycol.
  65. The pharmaceutical composition of Claim 64, wherein the polyethylene glycol is polyethylene glycol 400.
  66. The pharmaceutical composition of Claim 65, wherein the polyethylene glycol comprises about 20% to about 30% by weight of the combined weight of the polyethylene glycol 400 and the tocopherol.
  67. A pharmaceutical composition comprising celecoxib; glyceryl ricinoleate; and a polysorbate.
  68. The pharmaceutical composition of Claim 67, wherein the polysorbate is polysorbate 80.
  69. The pharmaceutical composition of Claim 68, wherein the polysorbate 80 comprises about 20% to about 30% by weight of the combined weights of the polysorbate 80 and the glyceryl ricinoleate.
  70. A pharmaceutical composition comprising celecoxib; a first excipient which is C<sub>8</sub> and C<sub>10</sub> mono- and di-glycerides from coconut oil; a second excipient which is triacetin; and a third excipient which is a mixture containing about 90% by weight monoolein and about 10% by weight propylene glycol.
  71. The pharmaceutical composition of Claim 70, wherein the first excipient comprises about 60% to about 70% by weight of the first, second and third excipients; the second excipient comprises about 20% to about 30% by weight of the first, second

and third excipients; and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.

72. A pharmaceutical composition comprising celecoxib; a first excipient which is triacetin; a second excipient selected from the group consisting of acetylated monoglycerides, a mixture containing about 90% by weight monoolein and about 10% by weight propylene glycol, and triacetin; and a third excipient selected from the group consisting of acetylated monoglycerides, glycetyl trilaurate, triacetin, and triethanolamine.
73. The pharmaceutical composition of Claim 70, wherein the first excipient comprises about 60% to about 75% by weight of the first, second and third excipients; the second excipient comprises about 20% to about 30% by weight of the first, second and third excipients; and the third excipient comprises about 3% to about 15% by weight of the first, second and third excipients.
74. A pharmaceutical composition comprising celecoxib and an excipient selected from the group consisting of: acetylated monoglycerides, monoolein:propylene glycol (90:10), mono-/diglyceride from coconut oil (C8/C10), propylene glycol monocaprylate, caprylic/capric triglyceride, C8/C10 diesters of propylene glycol of coconut oil, castor oil, coconut oil, corn oil, cottonseed oil, PEG 60 almond glycerides, diacetylated monoglycerides, ethylene glycol, gelucire 33/01, glycerin, glycetyl linoleate, glycetyl oleate, glycetyl ricinoleate, hydrogenated coconut oil, oleoyl macrogol-6 glycerides; apricot kernel oil PEG-6 ester, linoleoyl macrogol-6 glycerides; corn oil PEG-6 ester, PEG-8 caprylic/capric glyceride; caprylocaproyl macrogol-8 glycerides, propylene glycol monolaurate, lecithin (high HLB), lecithin (low HLB), linoleic acid, mineral oil, myristyl alcohol, oleic acid, PEG-6 isostearate, olive oil, palm oil (palm butter), peanut oil, polyglycerol-3-diisostearate, polyglyceryl-6-dioleate, Ethosperse G-26 (Lonza), poloxamer 331, polyethylene glycol 1000 (PEG-20), polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, polyoxyl 20 stearate, polyoxyl 30 castor oil, polyoxyl 35 castor oil, polyoxyl 40 castor oil, polyoxyl 40 hydrogenated castor

oil, polyoxyl 40 stearate, polypropylene glycol (MW 725), polypropylene glycol (MW 2000), polysorbate 20, polysorbate 40, polysorbate 80, polysorbate 60, propylene glycol, safflower oil, sesame oil, sorbitan monolaurate, sorbitan monooleate, sorbitan trioleate, soybean oil, sunflower seed oil, polyoxyethylene glycerol trioleate, tocopherol, triacetin, triethanolamine, trilaurin (glyceryl trilaurate), vegetable oil (partially hydrogenated and hydrogenated), vitamin E TPGS, benzyl alcohol, benzyl benzoate, ethylene glycol monoethyl ether, and isopropanolamine.

75. The pharmaceutical composition according to claim 74, wherein:

- (a) the celecoxib is dissolved at a concentration of at least 50 mg/mL at room temperature;
- (b) the celecoxib is dissolved at a concentration of at least 50 mg/mL at 40 degrees C;
- (c) the celecoxib is dissolved at a concentration of at least 50 mg/mL at 60 degrees C; or
- (d) the celecoxib is dissolved at a concentration of at least 100 mg/mL at 40 degrees C.

76. A pharmaceutical composition comprising celecoxib at a concentration of at least 200 mg/mL, further comprising the excipients:

- (1) lauroglycol FCC, PEG 400, and lauroglycol FCC;
- (2) lauroglycol FCC, PEG 400, and polysorbate 80;
- (3) lauroglycol FCC, PEG 400, and span 20;
- (4) lauroglycol FCC, polyoxyl 35 castor oil, and poloxamer 331;
- (5) lauroglycol FCC, polyoxyl 35 castor oil, and PEG 400;
- (6) lauroglycol FCC, polyoxyl 35 castor oil, and PEG 20 stearate;
- (7) lauroglycol FCC, polyoxyl 35 castor oil, and polysorbate 80;
- (8) lauroglycol FCC, polysorbate 80, and PEG 400;
- (9) lauroglycol FCC, polysorbate 80, and PEG 20 stearate;
- (10) lauroglycol FCC, polysorbate 80, and polyoxyl 35 castor oil;
- (11) lauroglycol FCC, polysorbate 80, and polysorbate 80;

- (12) poloxamer 331, lauroglycol FCC, and lauroglycol FCC;
- (13) poloxamer 331, lauroglycol FCC, and poloxamer 331;
- (14) poloxamer 331, lauroglycol FCC, and polysorbate 80;
- (15) poloxamer 331, poloxamer 331, and lauroglycol FCC;
- (16) poloxamer 331, poloxamer 331, and poloxamer 331;
- (17) poloxamer 331, poloxamer 331, and sesame oil;
- (18) poloxamer 331, polysorbate 80, and span 20;
- (19) poloxamer 331, sesame oil, and lauroglycol FCC;
- (20) poloxamer 331, sesame oil, and poloxamer 331;
- (21) PEG 400, PEG 400, and PEG 400;
- (22) PEG 400, PEG 400, and span 20;
- (23) PEG 400, polyoxyl 35 castor oil, lauroglycol FCC;
- (24) PEG 400, span 20, and span 20;
- (25) span 20, PEG 400, and lauroglycol FCC;
- (26) span 20, PEG 400, and poloxamer 331;
- (27) span 20, PEG 400, and PEG 400;
- (28) span 20, PEG 400, and polyoxyl 35 castor oil;
- (29) span 20, PEG 400, and polysorbate 80;
- (30) span 20, PEG 400, and sesame oil;
- (31) span 20, PEG 400, and span 20;
- (32) span 20, polysorbate 80, and PEG 400;
- (33) polyoxyl 35 castor oil, lauroglycol FCC, and lauroglycol FCC;
- (34) polyoxyl 35 castor oil, lauroglycol FCC, and poloxamer 331;
- (35) polyoxyl 35 castor oil, lauroglycol FCC, and PEG 400;
- (36) polyoxyl 35 castor oil, lauroglycol FCC, and polyoxyl 35 castor oil;
- (37) polyoxyl 35 castor oil, lauroglycol FCC, and polysorbate 80;
- (38) polyoxyl 35 castor oil, lauroglycol FCC, and sesame oil;
- (39) polyoxyl 35 castor oil, lauroglycol FCC, and span 20;
- (40) polyoxyl 35 castor oil, poloxamer 331, and PEG 400;
- (41) polyoxyl 35 castor oil, poloxamer 331, and polyoxyl 35 castor oil;
- (42) polyoxyl 35 castor oil, poloxamer 331, and polysorbate 80;

- (43) polyoxyl 35 castor oil, poloxamer 331, and sesame oil;
- (44) polyoxyl 35 castor oil, poloxamer 331, and span 20;
- (45) polyoxyl 35 castor oil, PEG 400, and lauroglycol FCC;
- (46) polyoxyl 35 castor oil, PEG 400, and poloxamer 331;
- (47) polyoxyl 35 castor oil, PEG 400, and PEG 400;
- (48) polyoxyl 35 castor oil, PEG 400, and polyoxyl 35 castor oil;
- (49) polyoxyl 35 castor oil, PEG 400, and polysorbate 80;
- (50) polyoxyl 35 castor oil, PEG 400, and sesame oil;
- (51) polyoxyl 35 castor oil, PEG 400, and span 20;
- (52) polyoxyl 35 castor oil, polyoxyl 35 castor oil, and lauroglycol FCC;
- (53) polyoxyl 35 castor oil, polyoxyl 35 castor oil, and poloxamer 331;
- (54) polyoxyl 35 castor oil, polyoxyl 35 castor oil, and PEG 400;
- (55) polyoxyl 35 castor oil, polyoxyl 35 castor oil, and polyoxyl 35 castor oil;
- (56) polyoxyl 35 castor oil, polyoxyl 35 castor oil, and polysorbate 80;
- (57) polyoxyl 35 castor oil, polyoxyl 35 castor oil, and sesame oil;
- (58) polyoxyl 35 castor oil, polyoxyl 35 castor oil, and span 20;
- (59) polyoxyl 35 castor oil, polysorbate 80, and lauroglycol FCC;
- (60) polyoxyl 35 castor oil, polysorbate 80, and poloxamer 331;
- (61) polyoxyl 35 castor oil, polysorbate 80, and PEG 400;
- (62) polyoxyl 35 castor oil, polysorbate 80, and polyoxyl 35 castor oil;
- (63) polyoxyl 35 castor oil, polysorbate 80, and polysorbate 80;
- (64) polyoxyl 35 castor oil, polysorbate 80, and sesame oil;
- (65) polyoxyl 35 castor oil, polysorbate 80, and span 20;
- (66) polyoxyl 35 castor oil, span 20, and lauroglycol FCC;
- (67) polyoxyl 35 castor oil, span 20, and poloxamer 331;
- (68) polyoxyl 35 castor oil, span 20, and PEG 400;
- (69) polyoxyl 35 castor oil, span 20, and polyoxyl 35 castor oil;
- (70) polyoxyl 35 castor oil, span 20, and polysorbate 80;
- (71) polyoxyl 35 castor oil, span 20, and sesame oil;
- (72) polyoxyl 35 castor oil, span 20, and span 20;

- (73) polysorbate 80, lauroglycol FCC, and lauroglycol FCC;
- (74) polysorbate 80, lauroglycol FCC, and PEG 400;
- (75) polysorbate 80, lauroglycol FCC, and polyoxyl 35 castor oil;
- (76) polysorbate 80, lauroglycol FCC, and polysorbate 80;
- (77) polysorbate 80, lauroglycol FCC, and sesame oil;
- (78) polysorbate 80, lauroglycol FCC, and span 20;
- (79) polysorbate 80, poloxamer 331, and PEG 400;
- (80) polysorbate 80, poloxamer 331, and polysorbate 80;
- (81) polysorbate 80, PEG 400, and lauroglycol FCC;
- (82) polysorbate 80, PEG 400, and poloxamer 331;
- (83) polysorbate 80, PEG 400, and PEG 400;
- (84) polysorbate 80, PEG 400, and polyoxyl 35 castor oil;
- (85) polysorbate 80, PEG 400, and polysorbate 80;
- (86) polysorbate 80, PEG 400, and sesame oil;
- (87) polysorbate 80, PEG 400, and span 20;
- (88) polysorbate 80, polyoxyl 35 castor oil, and lauroglycol FCC;
- (89) polysorbate 80, polyoxyl 35 castor oil, and poloxamer 331;
- (90) polysorbate 80, polyoxyl 35 castor oil, and PEG 400;
- (91) polysorbate 80, polyoxyl 35 castor oil, and polyoxyl 35 castor oil;
- (92) polysorbate 80, polyoxyl 35 castor oil, and polysorbate 80;
- (93) polysorbate 80, polyoxyl 35 castor oil, and sesame oil;
- (94) polysorbate 80, polyoxyl 35 castor oil, and span 20;
- (95) polysorbate 80, polysorbate 80, and lauroglycol FCC;
- (96) polysorbate 80, polysorbate 80, and poloxamer 331;
- (97) polysorbate 80, polysorbate 80, and PEG 400;
- (98) polysorbate 80, polysorbate 80, and polyoxyl 35 castor oil;
- (99) polysorbate 80, polysorbate 80, and polysorbate 80;
- (100) polysorbate 80, polysorbate 80, and sesame oil;
- (101) polysorbate 80, polysorbate 80, and span 20;
- (102) polysorbate 80, span 20, and lauroglycol FCC;
- (103) polysorbate 80, span 20, and poloxamer 331;

- (104) polysorbate 80, span 20, and PEG 400;
- (105) polysorbate 80, span 20, and polyoxyl 35 castor oil;
- (106) polysorbate 80, span 20, and polysorbate 80;
- (107) polysorbate 80, span 20, and sesame oil;
- (108) polysorbate 80, span 20, and span 20;
- (109) polyoxyl 35 castor oil and lauroglycol FCC;
- (110) polysorbate 80 and lauroglycol FCC;
- (111) poloxamer 331 and poloxamer 331;
- (112) polysorbate 80 and poloxamer 331;
- (113) PEG 400 and PEG 400;
- (114) polyoxyl 35 castor oil and PEG 400;
- (115) polysorbate 80 and PEG 400;
- (116) polyoxyl 35 castor oil and polyoxyl 35 castor oil;
- (117) polysorbate 80 and polyoxyl 35 castor oil;
- (118) PEG 400 and polysorbate 80;
- (119) polyoxyl 35 castor oil and polysorbate 80;
- (120) polysorbate 80 and polysorbate 80;
- (121) poloxamer 331 and sesame oil;
- (122) PEG 400 and span 20;
- (123) polyoxyl 35 castor oil and span 20;
- (124) polysorbate 80 and span 20;
- (125) poloxamer 331 and Capmul MCM;
- (126) PEG 400 and Capmul MCM;
- (127) polyoxyl 35 castor oil and Capmul MCM;
- (128) polysorbate 80 and Capmul MCM;
- (129) PEG 400 and Softigen 701;
- (130) polyoxyl 35 castor oil and softigen 701;
- (131) polysorbate 80 and softigen 701;
- (132) poloxamer 331 and triacetin;
- (133) PEG 400 and triacetin;
- (134) polyoxyl 35 castor oil and triacetin;

- (135) polysorbate 80 and triacetin;
- (136) PEG 400 and triethanolamine;
- (137) polyoxyl 35 castor oil and tocopherol;
- (138) polysorbate 80 and tocopherol;
- (139) PEG 400 and Croval A-70;
- (140) polyoxyl 35 castor oil and Croval A-70;
- (141) polysorbate 80 and Croval A-70;
- (142) poloxamer 331 and olepal isosteariques;
- (143) polyoxyl 35 castor oil and olepal isosteariques;
- (144) Croval A-70 and lauroglycol FCC;
- (145) olepal isosteariques and lauroglycol FCC;
- (146) olepal isosteariques and poloxamer 331;
- (147) Capmul MCM and PEG 400;
- (148) triacetin and PEG 400;
- (149) triethanolamine and PEG 400;
- (150) tocopherol and PEG 400;
- (151) Croval A-70 and PEG 400;
- (152) Capmul MCM and PEG 20 stearate;
- (153) triacetin and polyoxyl 35 castor oil;
- (154) Croval A-70 and polyoxyl 35 castor oil;
- (155) olepal isosteariques and polyoxyl 35 castor oil;
- (156) Softigen 701 and polysorbate 80;
- (157) Croval A-70 and polysorbate 80;
- (158) olepal isosteariques and polysorbate 80;
- (159) olepal isosteariques and sesame oil;
- (160) Croval A-70 and span 20;
- (161) triethanolamine and Capmul MCM;
- (162) Croval A-70 and Capmul MCM;
- (163) olepal isosteariques and Capmul MCM;
- (164) olepal isosteariques and coconut oil;
- (165) Croval A-70 and Softigen 701;

- (166) olepal isosteariques and Softigen 701;
- (167) Croval A-70 and triacetin;
- (168) olepal isosteariques and triacetin;
- (169) Croval A-70 and tocopherol;
- (170) olepal isosteariques and tocopherol;
- (171) triacetin and Croval A-70;
- (172) olepal isosteariques and Croval A-70;
- (173) triacetin and olepal isosteariques;
- (174) Croval A-70 and olepal isosteariques; or
- (175) olepal isosteariques and olepal isosteariques.

77. The pharmaceutical composition according to claim 76, wherein:

- (a) the excipients of compositions (1) through (108) are in the ratio of 64.5:25.8:9.7; or
- (b) the excipients of compositions (109) through (175) are in the ratio of 3:1.

78. A pharmaceutical composition comprising celecoxib and an excipient selected from the group consisting of: acetylated monoglycerides, monoolein:propylene glycol (90:10), mono-/diglyceride from coconut oil (C8/C10), glyceryl ricinoleate, lecithin, polyglyceryl-6 dioleate, propylene glycol, triacetin, triethanolamine, glyceryl trilaurate, and isopropanolamine.

79. The pharmaceutical composition according to claim 78, wherein:

- (a) the celecoxib is dissolved at a concentration of at least 50 mg/mL at room temperature;
- (b) the celecoxib is dissolved at a concentration of at least 50 mg/mL at 40 degrees C;
- (c) the celecoxib is dissolved at a concentration of at least 50 mg/mL at 60 degrees C; or

(d) the celecoxib is dissolved at a concentration of at least 100 mg/mL at 40 degrees C.

80. A pharmaceutical composition comprising celecoxib at a concentration of at least 200 mg/mL, further comprising the excipients:

- (a) Capmul MCM, triacetin, and monoolein:propylene glycol (90:10);
- (b) triacetin, acetylated monoglycerides, and acetylated monoglycerides;
- (c) triacetin, acetylated monoglycerides, and trilaurin;
- (d) triacetin, Arlacel 186, and acetylated monoglycerides;
- (e) triacetin, triacetin, and acetylated monoglycerides;
- (f) triacetin, triacetin, and triacetin; or
- (g) triacetin, triacetin, and triethanolamine.

81. The pharmaceutical composition according to claim 80, wherein:

- (a) the excipients of compositions (a) through (f) are in the ratio of 64.5:25.8:9.7; or
- (b) the excipients of composition (g) are in the ratio of 69.6:25.3:5.1.

82. A method of treating a subject in need of celecoxib, comprising the step of administering to the subject a pharmaceutical composition as described in any one of Claims 1 to 81.